Genotypic investigation of Clostridium difficile in Prince Edward Island

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 6, 2008, Pages 409-412

  Martin, H ^a   Abbott, L P ^b   Low, D E ^a   Willey, B ^c   Mulvey, M ^d   Weese, J Scott ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Prince Edward Island   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Clostridium difficile; Microbiology; Molecular epidemiology

Indexed keywords

TOXIN;

ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FECES CULTURE; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; NORTH AMERICA; RIBOTYPING; TOXIN ANALYSIS; TOXIN SYNTHESIS;

EID: 58149213968     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/848045     Document Type: Article

References (33)

1. Pépin J, Valiquette L, Alary M, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171:466-72.
2. McDonald L, Killgore G, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
3. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 2007;13:1058-64.
4. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-5.
5. Kuijper E, van Dissel J, Wilcox M. Clostridium difficile: Changing epidemiology and new treatment options. Curr Opin Infect Dis 2007;20:376-83.
6. Mulvey M, Miller M, Gravel D, et al. Molecular epidemiology of Clostridium difficile in Canadian hospitals, 2004-2005. The 2nd International Clostridium difficile Symposium. Maribor, June 6 to 9, 2007.
7. Martin H, Staempfli H, Willey B, et al. Characterization of Clostridium difficile from patients in Ontario hospitals. The 2nd International Clostridium difficile Symposium. Maribor, June 6 to 9, 2007.
8. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007;102:2781-8.
9. Loo V, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
10. Arroyo L, Rousseau J, Willey B, et al. Use of a selective enrichment broth to recover Clostridium difficile from stool swabs stored under different conditions. J Clin Microbiol 2005;43:5341-3.
11. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit J. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999;175:261-6.
12. Kato H, Kato N, Watanabe K, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998;36:2178-82.
13. Lemee L, Dhalluin A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004;42:5710-4.
14. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000;186:307-12.
15. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002;40:3470-5.
16. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998;36:2240-7.
17. Klaassen CH, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: Pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol 2002;40:101-4.
18. Hubert B, Loo V, Bourgault A, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C difficile-associated disease in Quebec. Clin Infect Dis 2007;44:238-44.
19. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84.
20. Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: A case-case study. PLoS ONE 2008;3:e1812.
21. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007;64:1274-88.
22. MacCannell D, Louie T, Gregson D, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 2006;44:2147-52.
23. Curry SR, Marsh JW, Muto CA, O'Leary MM, Pasculle AW, Harrison LH. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007;45:215-21.
24. Jhung MA, Thompson A, Killgore G, et al. An emerging Clostridium difficile toxinotype in humans and food animals. The 2nd International Clostridium difficile Symposium. Maribor, June 6 to 9, 2007.
25. Goorhuis A, Debast SB, van Leengoed LA, et al. Clostridium difficile PCR ribotype 078: An emerging strain in humans and in pigs? J Clin Microbiol 2008;46:1157.
26. Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007;13:1048-57.
27. Barbut F, Decré D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005;54:181-5.
28. Gonçalves C, Decré D, Barbut F, Burghoffer B, Petit J. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004;42:1933-9.
29. Rupnik M, Grabnar M, Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe 2003;9:289-94.
30. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007;45:695-703.
31. Alfa M, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:2706-14.
32. Bidet P, Lalande V, Salauze B, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000;38:2484-7.
33. Northey G, Gal M, Rahmati A, Brazier J. Subtyping of Clostridium difficile PCR ribotype 001 by REP-PCR and PFGE. J Med Microbiol 2005;54:543-7.